Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zorifertinib + Osimertinib in Advanced NSCLC With Meningeal Progression
NCT07361705Phase 1Recruiting
- Sponsor
- Alpha Biopharma
- Start
- Jan 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zorifertinib in non-small cell lung cancer (NSCLC), sponsored by Alpha Biopharma. Primary endpoint: Dose-Limiting Toxicities at 21 days. Started Jan 2026; status: recruiting.
02
Drugs
zorifertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07361705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361705.